{"protocolSection":{"identificationModule":{"nctId":"NCT01344447","orgStudyIdInfo":{"id":"14607"},"secondaryIdInfos":[{"id":"2010-023001-36","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Gadobutrol Enhanced MRA of the Supra-aortic Vessels","officialTitle":"Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels","acronym":"GEMSAV"},"statusModule":{"statusVerifiedDate":"2018-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-05-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-05-28","type":"ACTUAL"},"completionDateStruct":{"date":"2014-05-28","type":"ACTUAL"},"studyFirstSubmitDate":"2011-04-05","studyFirstSubmitQcDate":"2011-04-28","studyFirstPostDateStruct":{"date":"2011-04-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-05-27","resultsFirstSubmitQcDate":"2015-07-29","resultsFirstPostDateStruct":{"date":"2015-08-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-12-10","lastUpdatePostDateStruct":{"date":"2019-01-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.\n\nThis study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.\n\nMRA and CTA images will be collected for an independent review (blinded read)."},"conditionsModule":{"conditions":["Carotid Stenosis"],"keywords":["Supra-aortic vascular disease","MRA","CTA","Males and females aged 18 years or older","Stroke","Transient Ischemic Attack (TIA)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":479,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadovist, BAY86-4875)"]}],"interventions":[{"type":"DRUG","name":"Gadobutrol (Gadovist, BAY86-4875)","description":"A single bolus injection of approx. 0.1mmol/kg","armGroupLabels":["Arm 1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Each vascular segment was visualized using unenhanced MRA and gadobutrol-enhanced MRA, characterized by the on-site investigators, three independent blinded readers (BR) (BR 1, BR 2 and BR 3) and majority readers (the outcome determined by at least two of the blinded readers). A segment was assessable if it was visualized along its entire length and if any region of stenosis, was measured reliably. There were 21 segments of the supra-aortic arteries assessed per participant.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the standard of reference (SoR) (computed tomographic angiography \\[CTA\\]; blinded readers). This was determined using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the SoR (CTA; blinded readers). This was determined using the NASCET criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Minimum Gadobutrol Performance for Specificity: Specificity > 50%","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.","timeFrame":"Images were taken pre-injection and post-injection"}],"secondaryOutcomes":[{"measure":"Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images","description":"The segment reduction in diameter (DIA) of greater than 10% was considered abnormal and measured. The diameter of each of these abnormal segments was measured using electronic calipers (perpendicular to the long axis of the vessel) at the point of most severe stenosis within each segment. Mean of vessel diameters was calculated by segment separately for CTA and MRA readers. For ease of expression, the following abbreviations will be used: Diameter (DIA), Blinded Reader (BR), Clinical Investigator (CI).","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"The Percentage of Segments With Artifacts Presence","description":"Artifacts were collected for the MRA images on a segmental basis.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Artifacts on a Segment Basis by Blinded Reader 1","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Artifacts on a Segment Basis by Blinded Reader 2","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Artifacts on a Segment Basis by Blinded Reader 3","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Location within a segment was based on the point of greatest stenosis and was recorded for stenosis \\>=70% (including occlusions) as: - At the bifurcation or proximal origin of a segment (occlusion proximal to the origin of the segment); - Within 5 mm of the bifurcation or proximal origin of a segment; - Beyond 5 mm from the bifurcation or proximal origin of a segment.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"The length of stenosis was based on the most proximal (first point) in a segment where a stenosis exceeded 10% and the most distal point (last point) in the segment where a stenosis exceeded 10%. If a stenosis spanned more than one segment then the measurement was only included to the beginning or end (boundary) of the segment being evaluated. If there was no stenosis of \\>=70% in a segment then the length was designated as 0.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease","description":"Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease","description":"Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present. If there were tandem (serial) stenosis in a vessel then the secondary signs were assigned to the stenosis of \\>=70% that was proximal and closest in proximity to the secondary sign.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Diagnostic confidence was evaluated to determine the level of certainty that the blinded readers assigned to a diagnosis for each segment. This was defined as the degree of confidence that the information on the MRA images represented the true and complete clinical picture of a particular segment. The degree of confidence was rated on a 4-point scale: 1 = Not confident, 2 = Somewhat confident, 3 = Confident, and 4 = Very confident.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","description":"A measure of diagnostic value was the reduction in the number of additional diagnostic imaging studies recommended/ordered. The clinical investigators and the blinded readers were asked if they would have recommended an additional imaging study for each participant and was recorded.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","timeFrame":"Images were taken pre-injection and post-injection"},{"measure":"Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","timeFrame":"Images were taken pre-injection and post-injection"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects, aged 18 years and older\n* Any of the following:\n\n  * Known or suspected supra-aortic arterial disease based on:\n\n    * Prior stroke\n    * Transient ischemic attack (TIA)\n    * Amaurosis Fugax (transient monocular blindness)\n  * Referred for evaluation of any supra-aortic vessel (for clinically significant stenosis)\n  * Follow-up for a stent in a supra-aortic vessel\n  * Prior imaging study (CTA or ultrasound) showing ≥ 50% stenosis of a supra-aortic vessel segment (within 60 days before consent). The proportion of subjects with positive disease (determined by the investigator, based on CTA or ultrasound) will be monitored during the study, and enrolment may be further restricted to require ≥ 70% stenosis to ensure that overall there are an adequate number of subjects with clinically significant disease for the evaluation of study endpoints.\n* Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography \\[CE MRA\\] examination with gadobutrol\n* Willingness and ability to follow directions and complete all study procedures specified in the protocol\n* Females of childbearing potential only: Negative pregnancy test on the day of the MRA before the administration of study drug\n\nExclusion Criteria:\n\n* Pregnant or nursing (including pumping for storage and feeding)\n* Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study\n* Previous enrollment into this study or into any other Bayer sponsored study using gadobutrol\n* Contraindication to the MRA examinations (e.g. inability to hold breath; severe arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other metallic devices not approved for MRI)\n* Contraindication to the use of Gd-containing contrast agents (including subjects with suspicion for or known to have Nephrogenic Systemic Fibrosis \\[NSF\\])\n* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents\n* Received any contrast agent within 72 hours before the study MRA, or scheduled receipt of any contrast agent within 24 hours after the study MRA (Note: This applies also to a CTA potentially scheduled during the course of the study.)\n* Estimated glomerular filtration rate (eGFR) value \\< 30 ml/min/1.73 m2 derived from a serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from participation. Use the value obtained prior to and closest to the time of the MRA, if there are multiple creatinine values. (Do not use the core lab value if not available prior to the MRA.)\n* Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or occurring in the peri-operative liver transplantation period\n* Severe cardiovascular disease (e.g. acute myocardial infarction \\[\\< 14 days\\], unstable angina, congestive heart failure New York Heart Association class IV) or known long QT syndrome\n* Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery)\n* Scheduled or potentially expected for the period between the CTA and gadobutrol MRA:\n\n  * Any procedure that may alter the MRA or CTA interpretation, or\n  * Any interventional or surgical procedure involving the supra-aortic vessels","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Tucson","state":"Arizona","zip":"85724","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"city":"Jacksonville","state":"Florida","zip":"32209","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"city":"Savannah","state":"Georgia","zip":"31406","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"city":"Ann Arbor","state":"Michigan","zip":"48109-0330","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"city":"Jackson","state":"Mississippi","zip":"39216","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"city":"Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"city":"Providence","state":"Rhode Island","zip":"02903","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"city":"Memphis","state":"Tennessee","zip":"38104","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"city":"Adrogué","state":"Buenos Aires","zip":"B1846DWA","country":"Argentina","geoPoint":{"lat":-34.80041,"lon":-58.38384}},{"city":"Buenos Aires","state":"Ciudad Auton. De Buenos Aires","zip":"C1115AAB","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"city":"Buenos Aires","state":"Ciudad Auton. De Buenos Aires","zip":"C1425BEE","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"city":"New Lambton Heights","state":"New South Wales","zip":"2305","country":"Australia","geoPoint":{"lat":-32.92466,"lon":151.69364}},{"city":"Clayton","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.91667,"lon":145.11667}},{"city":"Parkville","state":"Victoria","zip":"3052","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"city":"Innsbruck","state":"Tirol","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"city":"Wien","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Brno","zip":"62500","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"city":"Brest Cedex","zip":"29609","country":"France","geoPoint":{"lat":48.3903,"lon":-4.48628}},{"city":"BRON Cedex","zip":"69677","country":"France","geoPoint":{"lat":45.73333,"lon":4.91667}},{"city":"Marseille","zip":"13385","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"city":"Paris Cedex 15","zip":"75908","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Karlsruhe","state":"Baden-Württemberg","zip":"76133","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"city":"Augsburg","state":"Bayern","zip":"865156","country":"Germany","geoPoint":{"lat":48.37154,"lon":10.89851}},{"city":"Erlangen","state":"Bayern","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"city":"Münster","state":"Nordrhein-Westfalen","zip":"48145","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"city":"Jena","state":"Thüringen","zip":"07740","country":"Germany","geoPoint":{"lat":50.92878,"lon":11.5899}},{"city":"Ferrara","state":"Emilia-Romagna","zip":"44023","country":"Italy","geoPoint":{"lat":44.83804,"lon":11.62057}},{"city":"Roma","state":"Lazio","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Catania","state":"Sicilia","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Massa-Carrara","state":"Toscana","zip":"54100","country":"Italy"},{"city":"Aosta","state":"Valle d'Aosta","zip":"11100","country":"Italy","geoPoint":{"lat":45.73764,"lon":7.31722}},{"city":"Venezia","state":"Veneto","zip":"30174","country":"Italy","geoPoint":{"lat":45.43713,"lon":12.33265}},{"city":"Donggu,","state":"Gwangju Gwang''yeogsi","zip":"61469","country":"Korea, Republic of"},{"city":"Seoul","zip":"03722","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"05505","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"06351","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Bydgoszcz","zip":"85-094","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"city":"Lodz","zip":"90-153","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"city":"Warszawa","zip":"02-097","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"city":"Wroclaw","zip":"50-556","country":"Poland","geoPoint":{"lat":51.1,"lon":17.03333}},{"city":"Linköping","zip":"581 85","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"city":"Uppsala","zip":"751 85","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"city":"St. Gallen","state":"Sankt Gallen","zip":"9007","country":"Switzerland","geoPoint":{"lat":47.42391,"lon":9.37477}},{"city":"Antalya","zip":"07059","country":"Turkey","geoPoint":{"lat":36.90812,"lon":30.69556}},{"city":"Erzurum","zip":"25240","country":"Turkey","geoPoint":{"lat":39.90861,"lon":41.27694}},{"city":"Istanbul","zip":"34093","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here to find information about studies related to Bayer Healthcare products conducted in Europe","url":"http://www.clinicaltrialsregister.eu/"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of 504 participants screened, 17 did not complete screening; due to screen failure in 6, consent withdrawal in 6 and other reasons in 5 participants. Of 487 participants assigned to treatment, 479 received study drug and 8 prematurely terminated due to adverse event in 7 participants, and other reason in 1 participant.","recruitmentDetails":"The study was conducted at 56 study centers in 14 countries, between 12 May 2011 (first participant first visit) and 28 May 2014 (last participant last visit).","groups":[{"id":"FG000","title":"Gadobutrol (Gadavist, BAY 86-4875)","description":"Gadobutrol was administered to all participants receiving study drug at the standard dose of 0.1 millimole per kilogram (mmol/kg) body weight (BW) by single intravenous (IV) bolus injection. During the course of the study, non-contrast MRA images were obtained before the administration of gadobutrol, and gadobutrol-enhanced MRA images were obtained after injection."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Participant received study drug; Safety analysis set","numSubjects":"479"}]},{"type":"Fulfilled Requirement of FAS Population","achievements":[{"groupId":"FG000","comment":"Full Analysis Set (FAS)","numSubjects":"457"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"471"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"The contrast was not seen","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"MRA unsuccessful","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Bolus tracking failed","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Error of power injector","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Gadobutrol (Gadavist, BAY 86-4875)","description":"Gadobutrol was administered to all participants receiving study drug at the standard dose of 0.1 millimole per kilogram (mmol/kg) body weight (BW) by single intravenous (IV) bolus injection. During the course of the study, non-contrast MRA images were obtained before the administration of gadobutrol, and gadobutrol-enhanced MRA images were obtained after injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"479"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.2","spread":"10"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"<45 years","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]},{"title":"45-64 years","categories":[{"measurements":[{"groupId":"BG000","value":"155"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"315"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"167"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"312"}]}]}]},{"title":"Baseline Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76.0","spread":"14.5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Each vascular segment was visualized using unenhanced MRA and gadobutrol-enhanced MRA, characterized by the on-site investigators, three independent blinded readers (BR) (BR 1, BR 2 and BR 3) and majority readers (the outcome determined by at least two of the blinded readers). A segment was assessable if it was visualized along its entire length and if any region of stenosis, was measured reliably. There were 21 segments of the supra-aortic arteries assessed per participant.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9597"},{"groupId":"OG001","value":"9597"}]}],"classes":[{"title":"Majority reader","categories":[{"measurements":[{"groupId":"OG000","value":"95.0"},{"groupId":"OG001","value":"72.7"}]}]},{"title":"Blinded reader 1","categories":[{"measurements":[{"groupId":"OG000","value":"88.2"},{"groupId":"OG001","value":"24.4"}]}]},{"title":"Blinded reader 2","categories":[{"measurements":[{"groupId":"OG000","value":"94.9"},{"groupId":"OG001","value":"75.3"}]}]},{"title":"Blinded reader 3","categories":[{"measurements":[{"groupId":"OG000","value":"97.4"},{"groupId":"OG001","value":"82.4"}]}]},{"title":"Clinical investigators","categories":[{"measurements":[{"groupId":"OG000","value":"97.0"},{"groupId":"OG001","value":"78.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Majority reader; Superiority analysis; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"McNemar","statisticalComment":"Cluster adjusted McNemar","paramType":"Percentage difference","paramValue":"22.3","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"20.4","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 1; Superiority analysis; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"McNemar","statisticalComment":"Cluster adjusted McNemar","paramType":"Percentage difference","paramValue":"63.8","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"60.9","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 2; Superiority analysis; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"McNemar","statisticalComment":"Cluster adjusted McNemar","paramType":"Percentage difference","paramValue":"19.6","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"17.8","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 3; Superiority analysis; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"McNemar","statisticalComment":"Cluster adjusted McNemar","paramType":"Percentage difference","paramValue":"15.0","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"13.3","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Clinical investigator; Superiority analysis; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"McNemar","statisticalComment":"Cluster adjusted McNemar","paramType":"Percentage difference","paramValue":"18.5","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"16.5","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."}]},{"type":"PRIMARY","title":"Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the standard of reference (SoR) (computed tomographic angiography \\[CTA\\]; blinded readers). This was determined using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.","populationDescription":"FAS; in below table, \"n/n\" signifies the number of participants/segments that were evaluable in specified category of each group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of sensitivity","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Non-contrast MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"238"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"297"}]}],"classes":[{"title":"Majority reader (n=141/158)","categories":[{"measurements":[{"groupId":"OG000","value":"60.1"},{"groupId":"OG001","value":"54.4"}]}]},{"title":"Blinded reader 1 (n=141/158)","categories":[{"measurements":[{"groupId":"OG000","value":"59.5"},{"groupId":"OG001","value":"54.4"}]}]},{"title":"Blinded reader 2 (n=141/158)","categories":[{"measurements":[{"groupId":"OG000","value":"59.5"},{"groupId":"OG001","value":"54.1"}]}]},{"title":"Blinded reader 3 (n=141/158)","categories":[{"measurements":[{"groupId":"OG000","value":"58.2"},{"groupId":"OG001","value":"55.7"}]}]},{"title":"Clinical investigators (n=238/297)","categories":[{"measurements":[{"groupId":"OG000","value":"60.9"},{"groupId":"OG001","value":"39.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Majority reader; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"5.7","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.6","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 1; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"5.1","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.4","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 2; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"5.1","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.7","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 3; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"3.2","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.9","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Clinical investigator; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"21.5","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.1","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."}]},{"type":"PRIMARY","title":"Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the SoR (CTA; blinded readers). This was determined using the NASCET criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.","populationDescription":"FAS; in below table, \"n/n\" signifies the number of participants/segments that were evaluable in specified category of each group if it varies from \"Number of participants/segments analyzed\".","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of specificity","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Non-contrast MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9321"},{"groupId":"OG001","value":"9321"}]}],"classes":[{"title":"Majority reader (n=457/9321)","categories":[{"measurements":[{"groupId":"OG000","value":"96.1"},{"groupId":"OG001","value":"87.3"}]}]},{"title":"Blinded reader 1 (n=457/9321)","categories":[{"measurements":[{"groupId":"OG000","value":"92.0"},{"groupId":"OG001","value":"61.7"}]}]},{"title":"Blinded reader 2 (n=457/9321)","categories":[{"measurements":[{"groupId":"OG000","value":"94.7"},{"groupId":"OG001","value":"85.1"}]}]},{"title":"Blinded reader 3 (n=457/9321)","categories":[{"measurements":[{"groupId":"OG000","value":"96.7"},{"groupId":"OG001","value":"89.1"}]}]},{"title":"Clinical investigators (n=457/9133)","categories":[{"measurements":[{"groupId":"OG000","value":"98.1"},{"groupId":"OG001","value":"89.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Majority reader; The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"8.8","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.7","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 1; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"30.3","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"28.6","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 2; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"9.7","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.5","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Blinded reader 3; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"7.6","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.6","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."},{"groupIds":["OG000","OG001"],"groupDescription":"Clinical investigator; the percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"using a -7.5% non-inferiority margin","statisticalMethod":"The cluster-adjusted two-sided 95% CI","paramType":"Percentage difference","paramValue":"9.1","ciPctValue":"95.1","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.9","ciUpperLimitComment":"Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."}]},{"type":"PRIMARY","title":"Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.","populationDescription":"FAS; in below table, \"n/n\" signifies the number of participants/segments that were evaluable in specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of sensitivity","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"283"}]}],"classes":[{"title":"Majority reader (n=135/149)","categories":[{"measurements":[{"groupId":"OG000","value":"61.7"}]}]},{"title":"Blinded reader 1 (n=132/146)","categories":[{"measurements":[{"groupId":"OG000","value":"60.3"}]}]},{"title":"Blinded reader 2 (n=139/156)","categories":[{"measurements":[{"groupId":"OG000","value":"59.6"}]}]},{"title":"Blinded reader 3 (n=140/155)","categories":[{"measurements":[{"groupId":"OG000","value":"58.7"}]}]},{"title":"Clinical investigators (n=230/283)","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Majority reader","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"61.7","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"55.3"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 1","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"60.3","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"53.6"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 2","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"59.6","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"53.1"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 3","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"58.7","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"52.2"},{"groupIds":["OG000"],"groupDescription":"Clinical investigator","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"61.5","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"56.7"}]},{"type":"PRIMARY","title":"Minimum Gadobutrol Performance for Specificity: Specificity > 50%","description":"Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.","populationDescription":"FAS; in below table, \"n/n\" signifies the number of participants/segments that were evaluable in specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of specificity","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"8926"}]}],"classes":[{"title":"Majority reader (n=457/8805)","categories":[{"measurements":[{"groupId":"OG000","value":"98.0"}]}]},{"title":"Blinded reader 1 (n=444/8225)","categories":[{"measurements":[{"groupId":"OG000","value":"97.6"}]}]},{"title":"Blinded reader 2 (n=457/8844)","categories":[{"measurements":[{"groupId":"OG000","value":"97.2"}]}]},{"title":"Blinded reader 3 (n=457/9079)","categories":[{"measurements":[{"groupId":"OG000","value":"98.0"}]}]},{"title":"Clinical investigators (n=457/8926)","categories":[{"measurements":[{"groupId":"OG000","value":"99.2"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Majority reader","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"98.0","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"97.7"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 1","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"97.6","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"97.3"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 2","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"97.2","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"96.9"},{"groupIds":["OG000"],"groupDescription":"Blinded Reader 3","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"98.0","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"97.7"},{"groupIds":["OG000"],"groupDescription":"Clinical investigator","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"One sided 95.1% confidence interval","paramType":"percentage","paramValue":"99.2","ciPctValue":"95.1","ciNumSides":"ONE_SIDED","ciLowerLimit":"98.9"}]},{"type":"SECONDARY","title":"Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images","description":"The segment reduction in diameter (DIA) of greater than 10% was considered abnormal and measured. The diameter of each of these abnormal segments was measured using electronic calipers (perpendicular to the long axis of the vessel) at the point of most severe stenosis within each segment. Mean of vessel diameters was calculated by segment separately for CTA and MRA readers. For ease of expression, the following abbreviations will be used: Diameter (DIA), Blinded Reader (BR), Clinical Investigator (CI).","populationDescription":"FAS; Number of participants/segments analyzed in below ordered categories (Normal-BRs; Narrowest-BRs; Normal-CIs; Narrowest-CIs) in Enhanced MRA group was 457/6182, 457/6182, 419/1361, 419/1352 respectively; in Unenhanced MRA group was 455/4776, 455/4776, 367/989, 367/980 respectively; in CTA was 442/3158, 442/3158, 419/1569, 419/1555 respectively.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeter(s) (mm)","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-Enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"},{"id":"OG002","title":"Computed Tomographic Angiography"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"455"},{"groupId":"OG002","value":"442"}]}],"classes":[{"title":"Vessel DIA at normal point: BRs","categories":[{"measurements":[{"groupId":"OG000","value":"4.88","spread":"1.90"},{"groupId":"OG001","value":"4.33","spread":"1.53"},{"groupId":"OG002","value":"4.98","spread":"2.08"}]}]},{"title":"Vessel DIA at narrowest point: BRs","categories":[{"measurements":[{"groupId":"OG000","value":"3.23","spread":"1.54"},{"groupId":"OG001","value":"2.66","spread":"1.34"},{"groupId":"OG002","value":"3.00","spread":"1.50"}]}]},{"title":"Vessel DIA at normal point: CIs","categories":[{"measurements":[{"groupId":"OG000","value":"4.81","spread":"1.78"},{"groupId":"OG001","value":"4.54","spread":"1.58"},{"groupId":"OG002","value":"5.17","spread":"2.02"}]}]},{"title":"Vessel DIA at narrowest point: CIs","categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"1.37"},{"groupId":"OG001","value":"2.31","spread":"1.21"},{"groupId":"OG002","value":"2.68","spread":"1.62"}]}]}],"analyses":[{"groupIds":["OG001","OG002"],"groupDescription":"CTA Minus Unenhanced MRA for blinded Reader on vessel DIA at normal point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.21","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.80"},{"groupIds":["OG000","OG002"],"groupDescription":"CTA minus Gadobutrol-Enhanced MRA for blinded reader on vessel DIA at normal point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.00","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.79"},{"groupIds":["OG001","OG002"],"groupDescription":"CTA minus Unenhanced MRA for blinded reader on vessel DIA at narrowest point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.29","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.87"},{"groupIds":["OG000","OG002"],"groupDescription":"CTA minus Gadobutrol-Enhanced MRA for blinded reader on vessel DIA at narrowest point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.01","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.80"},{"groupIds":["OG001","OG002"],"groupDescription":"CTA minus Unenhanced MRA for clinical investigators on vessel DIA at normal point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.48","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.98"},{"groupIds":["OG000","OG002"],"groupDescription":"CTA minus Gadobutrol-enhanced MRA for clinical investigators on vessel DIA at normal point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.33","dispersionType":"STANDARD_DEVIATION","dispersionValue":"1.01"},{"groupIds":["OG001","OG002"],"groupDescription":"CTA minus Unenhanced MRA for clinical investigators on vessel DIA at narrowest point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.02","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.81"},{"groupIds":["OG000","OG002"],"groupDescription":"CTA minus Gadobutrol-enhanced MRA for clinical investigators on vessel DIA at narrowest point","nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Mean Difference","paramType":"Diameter difference","paramValue":"0.11","dispersionType":"STANDARD_DEVIATION","dispersionValue":"0.79"}]},{"type":"SECONDARY","title":"The Percentage of Segments With Artifacts Presence","description":"Artifacts were collected for the MRA images on a segmental basis.","populationDescription":"Evaluable participants in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9821"},{"groupId":"OG001","value":"9552"}]}],"classes":[{"title":"Blinded reader 1","categories":[{"measurements":[{"groupId":"OG000","value":"46.6"},{"groupId":"OG001","value":"97.1"}]}]},{"title":"Blinded reader 2","categories":[{"measurements":[{"groupId":"OG000","value":"14.0"},{"groupId":"OG001","value":"54.9"}]}]},{"title":"Blinded reader 3","categories":[{"measurements":[{"groupId":"OG000","value":"16.2"},{"groupId":"OG001","value":"41.2"}]}]}]},{"type":"SECONDARY","title":"Types of Artifacts on a Segment Basis by Blinded Reader 1","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","populationDescription":"Participants in FAS with artifacts presence.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9821"},{"groupId":"OG001","value":"9552"}]}],"classes":[{"title":"Motion artifact","categories":[{"measurements":[{"groupId":"OG000","value":"18.6"},{"groupId":"OG001","value":"41.9"}]}]},{"title":"Venous opacification","categories":[{"measurements":[{"groupId":"OG000","value":"9.8"},{"groupId":"OG001","value":"0.8"}]}]},{"title":"Saturation artifact","categories":[{"measurements":[{"groupId":"OG000","value":"21.6"},{"groupId":"OG001","value":"38.2"}]}]},{"title":"Susceptibility artifacts","categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.2"}]}]},{"title":"Ringing artifact","categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"29.3"}]}]},{"title":"Bolus timing error","categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"4.0"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"9.3"},{"groupId":"OG001","value":"48.0"}]}]}]},{"type":"SECONDARY","title":"Types of Artifacts on a Segment Basis by Blinded Reader 2","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","populationDescription":"Participants in FAS with artifacts presence.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9821"},{"groupId":"OG001","value":"9552"}]}],"classes":[{"title":"Motion artifact","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"39.8"}]}]},{"title":"Venous opacification","categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"0.3"}]}]},{"title":"Saturation artifact","categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"24.5"}]}]},{"title":"Susceptibility artifacts","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"3.7"}]}]},{"title":"Ringing artifact","categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Bolus timing error","categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.3"}]}]}]},{"type":"SECONDARY","title":"Types of Artifacts on a Segment Basis by Blinded Reader 3","description":"The following types of artifacts were considered: Motion artifact (including pulsatility, breathing, swallowing), venous opacification, saturation artifact (for example \\[eg\\], in-plane flow, turbulence, dephasing, saturation band), susceptibility artifacts (including devices, eg, stents), ringing artifact (eg, bands), bolus timing error, and other (artifact not specified above or no artifact).","populationDescription":"Participants in FAS with artifacts presence.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","typeUnitsAnalyzed":"segments","denomUnitsSelected":"segments","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]},{"units":"segments","counts":[{"groupId":"OG000","value":"9821"},{"groupId":"OG001","value":"9552"}]}],"classes":[{"title":"Motion artifact","categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"13.2"}]}]},{"title":"Venous opacification","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"0.1"}]}]},{"title":"Saturation artifact","categories":[{"measurements":[{"groupId":"OG000","value":"13.8"},{"groupId":"OG001","value":"39.4"}]}]},{"title":"Susceptibility artifacts","categories":[{"measurements":[{"groupId":"OG000","value":"0.2"},{"groupId":"OG001","value":"0.5"}]}]},{"title":"Ringing artifact","categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"6.4"}]}]},{"title":"Bolus timing error","categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"0.4"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.1"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Location within a segment was based on the point of greatest stenosis and was recorded for stenosis \\>=70% (including occlusions) as: - At the bifurcation or proximal origin of a segment (occlusion proximal to the origin of the segment); - Within 5 mm of the bifurcation or proximal origin of a segment; - Beyond 5 mm from the bifurcation or proximal origin of a segment.","populationDescription":"Evaluable participants in FAS; in the below table, \"n\" signifies number of locations that were evaluable for the specified category of each group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"pecentage of location","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"At the bifurcation: BR 1 (n=353; 89)","categories":[{"measurements":[{"groupId":"OG000","value":"50.4"},{"groupId":"OG001","value":"59.6"}]}]},{"title":"At the bifurcation: BR 2 (n=429; 429)","categories":[{"measurements":[{"groupId":"OG000","value":"52.2"},{"groupId":"OG001","value":"58.7"}]}]},{"title":"At the bifurcation: BR 3 (n=525; 559)","categories":[{"measurements":[{"groupId":"OG000","value":"44.0"},{"groupId":"OG001","value":"54.2"}]}]},{"title":"Within 5 mm of the bifurcation: BR 1 (n=353; 89)","categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"12.4"}]}]},{"title":"Within 5 mm of the bifurcation: BR 2 (n=429; 429)","categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"10.7"}]}]},{"title":"Within 5 mm of the bifurcation: BR 3 (n=525; 559)","categories":[{"measurements":[{"groupId":"OG000","value":"34.7"},{"groupId":"OG001","value":"27.0"}]}]},{"title":"Beyond 5 mm of the bifurcation: BR 1 (n=353; 89)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9"},{"groupId":"OG001","value":"28.1"}]}]},{"title":"Beyond 5 mm of the bifurcation: BR 2 (n=429; 429)","categories":[{"measurements":[{"groupId":"OG000","value":"33.1"},{"groupId":"OG001","value":"30.5"}]}]},{"title":"Beyond 5 mm of the bifurcation: BR 3 (n=525; 559)","categories":[{"measurements":[{"groupId":"OG000","value":"21.3"},{"groupId":"OG001","value":"18.8"}]}]}]},{"type":"SECONDARY","title":"Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"The length of stenosis was based on the most proximal (first point) in a segment where a stenosis exceeded 10% and the most distal point (last point) in the segment where a stenosis exceeded 10%. If a stenosis spanned more than one segment then the measurement was only included to the beginning or end (boundary) of the segment being evaluated. If there was no stenosis of \\>=70% in a segment then the length was designated as 0.","populationDescription":"Evaluable participants in FAS; this outcome measure was analyzed on a segment basis, in the below table, \"n\" signifies number of segments that were evaluable for the specified category of each group.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeter(s)","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"Reader 1 (n=290; 66)","categories":[{"measurements":[{"groupId":"OG000","value":"11.26","spread":"11.77"},{"groupId":"OG001","value":"13.36","spread":"11.47"}]}]},{"title":"Reader 2 (n=315; 281)","categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"6.99"},{"groupId":"OG001","value":"7.18","spread":"6.07"}]}]},{"title":"Reader 3 (n=277; 268)","categories":[{"measurements":[{"groupId":"OG000","value":"4.89","spread":"4.69"},{"groupId":"OG001","value":"5.36","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease","description":"Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present.","populationDescription":"Evaluable participants in FAS; this outcome measure was analyzed on a segment basis, in below table, \"n\" signifies segments that were evaluable for the specified category of each group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of radiologic indicator","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"Reader 1 (n=9336; 9203)","categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"11.77"},{"groupId":"OG001","value":"0.7","spread":"11.47"}]}]},{"title":"Reader 2 (n=9444; 9177)","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"6.99"},{"groupId":"OG001","value":"2.0","spread":"6.07"}]}]},{"title":"Reader 3 (n=9285; 9009)","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"4.69"},{"groupId":"OG001","value":"2.7","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease","description":"Each segment was assessed for secondary signs of stenosis for diagnosis of clinically significant disease. The following indicators were considered for the MRA studies: - post-stenotic dilation or ulceration (segmental), - post-stenotic signal dropout, narrowing and intensity reduction, and - thrombus. Each of the three parameters were assessed as present or absent in the region distal to the stenosis. If they were found in any segment distal to the stenosis then they were assessed as present. If there were tandem (serial) stenosis in a vessel then the secondary signs were assigned to the stenosis of \\>=70% that was proximal and closest in proximity to the secondary sign.","populationDescription":"Evaluable participants in FAS; this outcome measure was analyzed on a segment basis, in below table, \"n\" signifies number of segments with presence of secondary radiologic indicators for the specified category of each group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of segments","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"Post-stenotic dilation: BR 1 (n=390; 63)","categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":"11.77"},{"groupId":"OG001","value":"20.6","spread":"11.47"}]}]},{"title":"Post-stenotic dilation: BR 2 (n=271; 188)","categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"6.99"},{"groupId":"OG001","value":"56.4","spread":"6.07"}]}]},{"title":"Post-stenotic dilation: BR 3 (n=236; 246)","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"4.69"},{"groupId":"OG001","value":"1.6","spread":"3.76"}]}]},{"title":"Post-stenotic signal dropout: BR 1 (n=390; 63)","categories":[{"measurements":[{"groupId":"OG000","value":"49.5"},{"groupId":"OG001","value":"77.8"}]}]},{"title":"Post-stenotic signal dropout: BR 2 (n=271; 188)","categories":[{"measurements":[{"groupId":"OG000","value":"25.5"},{"groupId":"OG001","value":"43.6"}]}]},{"title":"Post-stenotic signal dropout: BR 3(n=236; 246)","categories":[{"measurements":[{"groupId":"OG000","value":"92.8"},{"groupId":"OG001","value":"98.4"}]}]},{"title":"Thrombus: BR 1 (n=390; 63)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Thrombus: BR 2 (n=271; 188)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Thrombus: BR 3 (n=236; 246)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA","description":"Diagnostic confidence was evaluated to determine the level of certainty that the blinded readers assigned to a diagnosis for each segment. This was defined as the degree of confidence that the information on the MRA images represented the true and complete clinical picture of a particular segment. The degree of confidence was rated on a 4-point scale: 1 = Not confident, 2 = Somewhat confident, 3 = Confident, and 4 = Very confident.","populationDescription":"Evaluable participants in FAS; this outcome measure was analyzed on a segment basis, in below table, \"n\" signifies number of segments that were evaluable for the specified category of each group.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"456"}]}],"classes":[{"title":"Reader 1 (n=9408; 9231)","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.0"},{"groupId":"OG001","value":"1.3","spread":"0.6"}]}]},{"title":"Reader 2 (n=9535; 9301)","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.6"},{"groupId":"OG001","value":"2.2","spread":"0.9"}]}]},{"title":"Reader 3 (n=9539; 9302)","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.5"},{"groupId":"OG001","value":"2.4","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","description":"A measure of diagnostic value was the reduction in the number of additional diagnostic imaging studies recommended/ordered. The clinical investigators and the blinded readers were asked if they would have recommended an additional imaging study for each participant and was recorded.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"Reader 1","categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"11.77"},{"groupId":"OG001","value":"100.0","spread":"11.47"}]}]},{"title":"Reader 2","categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":"6.99"},{"groupId":"OG001","value":"98.2","spread":"6.07"}]}]},{"title":"Reader 3","categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"4.69"},{"groupId":"OG001","value":"83.2","spread":"3.76"}]}]},{"title":"Clinical investigators","categories":[{"measurements":[{"groupId":"OG000","value":"11.2"},{"groupId":"OG001","value":"43.1"}]}]}]},{"type":"SECONDARY","title":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","populationDescription":"Participants in FAS who were recommended for additional imaging studies.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"457"}]}],"classes":[{"title":"Non-contrast MRA","categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"11.77"},{"groupId":"OG001","value":"0","spread":"11.47"}]}]},{"title":"Contrast-enhanced MRA","categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":"6.99"},{"groupId":"OG001","value":"448","spread":"6.07"}]}]},{"title":"CTA","categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":"4.69"},{"groupId":"OG001","value":"4","spread":"3.76"}]}]},{"title":"Ultrasound","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"DSCA","categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"5"}]}]},{"title":"Nuclear medicine study","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","populationDescription":"Participants in FAS who were recommended for additional imaging studies.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"449"}]}],"classes":[{"title":"Non-contrast MRA","categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":"11.77"},{"groupId":"OG001","value":"2","spread":"11.47"}]}]},{"title":"Contrast-enhanced MRA","categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":"6.99"},{"groupId":"OG001","value":"415","spread":"6.07"}]}]},{"title":"CTA","categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":"4.69"},{"groupId":"OG001","value":"30","spread":"3.76"}]}]},{"title":"Ultrasound","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"DSCA","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}]},{"title":"Nuclear medicine study","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","populationDescription":"Participants in FAS who were recommended for additional imaging studies.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"380"}]}],"classes":[{"title":"Non-contrast MRA","categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"11.77"},{"groupId":"OG001","value":"0","spread":"11.47"}]}]},{"title":"Contrast-enhanced MRA","categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":"6.99"},{"groupId":"OG001","value":"64","spread":"6.07"}]}]},{"title":"CTA","categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":"4.69"},{"groupId":"OG001","value":"316","spread":"3.76"}]}]},{"title":"Ultrasound","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"DSCA","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nuclear medicine study","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","description":"An additional imaging study recommended was specified from the following list: Non-contrast MRA, Contrast-enhanced MRA, CTA, Ultrasound, Digital subtraction catheter angiogram (DSCA), and Nuclear medicine study.","populationDescription":"Participants in FAS who were recommended for additional imaging studies.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Images were taken pre-injection and post-injection","groups":[{"id":"OG000","title":"Gadobutrol-enhanced MRA"},{"id":"OG001","title":"Unenhanced MRA"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Non-contrast MRA","categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"11.77"},{"groupId":"OG001","value":"0","spread":"11.47"}]}]},{"title":"Contrast-enhanced MRA","categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"6.99"},{"groupId":"OG001","value":"142","spread":"6.07"}]}]},{"title":"CTA","categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"4.69"},{"groupId":"OG001","value":"51","spread":"3.76"}]}]},{"title":"Ultrasound","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"DSCA","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Nuclear medicine study","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"From the time the consent was signed until 24 (+/-6) hours follow-up after the study MRA but was continued until completion of the CTA in those participants who had the CTA performed after the MRA (as part of the study)","eventGroups":[{"id":"EG000","title":"Gadobutrol (Gadavist, BAY 86-4875)","description":"Gadobutrol was administered to all participants receiving study drug at the standard dose of 0.1 millimole per kilogram (mmol/kg) body weight (BW) by single intravenous (IV) bolus injection. During the course of the study, non-contrast MRA images were obtained before the administration of gadobutrol, and gadobutrol-enhanced MRA images were obtained after injection.","seriousNumAffected":1,"seriousNumAtRisk":479,"otherNumAffected":0,"otherNumAtRisk":479}],"seriousEvents":[{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":479}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Therapeutic Area Head","organization":"BAYER","email":"clinical-trials-contact@bayerhealthcare.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Brazil","Czech Republic"]},"conditionBrowseModule":{"meshes":[{"id":"D000016893","term":"Carotid Stenosis"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000002340","term":"Carotid Artery Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000001157","term":"Arterial Occlusive Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5485","name":"Ischemic Attack, Transient","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M6165","name":"Constriction, Pathologic","relevance":"LOW"},{"id":"M18928","name":"Carotid Stenosis","asFound":"Carotid Stenosis","relevance":"HIGH"},{"id":"M5284","name":"Carotid Artery Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}